The estimated Net Worth of Praveen Tyle is at least $1.91 Million dollars as of 28 February 2021. Mr. Tyle owns over 68,007 units of Lexicon Pharmaceuticals Inc stock worth over $232,123 and over the last 10 years he sold LXRX stock worth over $0. In addition, he makes $1,675,990 as Executive Vice President - Research and Development at Lexicon Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Tyle LXRX stock SEC Form 4 insiders trading
Praveen has made over 2 trades of the Lexicon Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 68,007 units of LXRX stock worth $114,932 on 28 February 2021.
The largest trade he's ever made was exercising 68,007 units of Lexicon Pharmaceuticals Inc stock on 28 February 2021 worth over $114,932. On average, Praveen trades about 4,878 units every 17 days since 2015. As of 28 February 2021 he still owns at least 137,351 units of Lexicon Pharmaceuticals Inc stock.
You can see the complete history of Mr. Tyle stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Praveen Tyle biography
Praveen Tyle Ph.D. serves as Executive Vice President - Research and Development of the Company. Dr. Tyle has been our executive vice president of research and development since May 2016. Dr. Tyle was previously a member of the executive management team at Osmotica Pharmaceutical Corp., serving as president and chief executive officer from January 2013 through April 2016 and prior to that as executive vice president and chief scientific officer. Prior to his service at Osmotica, Dr. Tyle held a series of scientific leadership positions within the pharmaceutical industry, including executive vice president and chief science officer for the United States Pharmacopeia, senior vice president and global head of research and development and business development and licensing at Novartis OTC, corporate senior vice president of global research and development and chief scientific officer at Bausch & Lomb Incorporated and vice president and global head of pharmaceutical sciences at Pharmacia Corporation. Dr. Tyle serves as director of Eyegate Pharmaceuticals, Inc. and Orient Europharma Ltd. Dr. Tyle received his B.Pharm. from the Indian Institute of Technology, Banaras Hindu University and his Ph.D. in pharmaceutics and pharmaceutical chemistry from the Ohio State University.
What is the salary of Praveen Tyle?
As the Executive Vice President - Research and Development of Lexicon Pharmaceuticals Inc, the total compensation of Praveen Tyle at Lexicon Pharmaceuticals Inc is $1,675,990. There are 1 executives at Lexicon Pharmaceuticals Inc getting paid more, with Lonnel Coats having the highest compensation of $3,870,290.
How old is Praveen Tyle?
Praveen Tyle is 60, he's been the Executive Vice President - Research and Development of Lexicon Pharmaceuticals Inc since 2016. There are 11 older and 7 younger executives at Lexicon Pharmaceuticals Inc. The oldest executive at Lexicon Pharmaceuticals Inc is Alan Nies, 82, who is the Independent Director.
What's Praveen Tyle's mailing address?
Praveen's mailing address filed with the SEC is 8800 TECHNOLOGY FOREST PLACE, , THE WOODLANDS, TX, 77381.
Insiders trading at Lexicon Pharmaceuticals Inc
Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc..., and Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.
What does Lexicon Pharmaceuticals Inc do?
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
What does Lexicon Pharmaceuticals Inc's logo look like?
Complete history of Mr. Tyle stock trades at AB Active ETFs Inc and Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc executives and stock owners
Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Lonnel Coats,
President, Chief Executive Officer, Director -
Praveen Tyle,
Executive Vice President - Research and Development -
Jeffrey Wade,
Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs -
Lonnel Coats,
CEO & Director -
Alan Main,
Executive Vice President, Commercial Supply Operations -
Jeffrey L. Wade J.D.,
Pres & CFO -
Dr. Alan J. Main Ph.D.,
Exec. VP of Innovation & Chemical Sciences -
Dr. Alan J. Main,
Exec. VP of Innovation & Chemical Sciences -
Brian T. Crum,
VP, Gen. Counsel & Sec. -
James Tessmer,
Vice President - Finance and Accounting -
Raymond Debbane,
Independent Chairman of the Board -
Samuel Barker,
Independent Director -
Frank Palantoni,
Independent Director -
Judith Swain,
Independent Director -
Philippe Amouyal,
Independent Director -
Robert Lefkowitz,
Independent Director -
Christopher Sobecki,
Independent Director -
Alan Nies,
Independent Director -
Dr. Robert J. Lefkowitz,
Consultant & Independent Director -
Brian Crum,
Vice President, General Counsel -
Dr. Craig B. Granowitz M.D., Ph.D.,
Sr. VP & Chief Medical Officer -
Kristen L. Alexander,
VP of Fin. & Accounting -
Chas Schultz,
Exec. Director of Corp. Communications & Patient Advocacy -
Sam L Barker,
Director -
Alexander A Santini,
EVP and CCO -
Pablo Lapuerta,
EVP and CMO -
International S.C.A.Wittouc...,
-
Us Partners Llc Ulys, L.L.C...,
-
Tamar D Howson,
EVP of Bus Dev -
Barry Mills,
Director -
Julia P Gregory,
EVP and CFO -
James R Phd Piggott,
SVP of Pharm Bio -
Lance K Ishimoto,
SVP, Intellectual Property -
Clayton Stuart Rose,
Director -
Public Equities, L.P.Artal ...,
-
Public Equities, L.P.Artal ...,
-
International S.C.A.Minne P...,
-
Diane E. Sullivan,
Director -
Thomas Garner,
SVP, Chief Commercial Officer -
Arthur T Sands,
Pres & CEO -
John Northcott,
VP, Marketing, Comm Strategy -
Cv Ulys, L.L.C.Debbane Raym...,
-
International S.C.A.Minne P...,
-
Brian P Zambrowicz,
EVP, Chief Scientific Officer -
Llc Invus, L.P.Invus Public...,
-
International S.C.A.Invus, ...,
-
Kathleen M Wiltsey,
Director -
Llc Invus, L.P.Invus Adviso...,
-
Philip M Brown,
SVP Clinical Development -
Steven Alan Tragash,
VP, Corporate Affairs -
Llc Invus, L.P.Invus Adviso...,
-
Ajay Bansal,
EVP Corp Dev and CFO -
Kristen Alexander,
VP, Finance and Accounting -
C.V. Invus,
Director -
Craig B Granowitz,
SVP, Chief Medical Officer -
Kenneth B. Kassler Taub,
SVP, Regulatory & QA -
Wendy Mc Dermott,
VP, Human Resources -
Kiernan Seth,
VP, Chief Commercial Officer -
Michael Exton,
Chief Executive Officer -
Brian Corrigan,
SVP, Regulatory & QA